Read here for more on the potential of RCUS's combination therapies for various cancers, with promising Phase 3 trials and ...

Invest in Arcus Biosciences for a strong buying opportunity with promising data, robust pipeline, and significant market ...

Precision BioSciences gains momentum as iECURE reports positive ECUR-506 data, and analysts forecast significant HBV ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Last month Arcus reported top -line phase 2 results with the TIGIT drug that it said warranted taking it forward into a phase 3 programme, but so far there's no word from Gilead on a buy-in.

Long term Arcus Biosciences, Inc. (NYSE:RCUS) shareholders know that all too well, since the share price is down considerably over three years. Unfortunately, they have held through a 65% decline ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies ...

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

Marcus Rashford 'dreams' of a move to Barcelona and has reportedly given them a deadline amid talks with another European ...

Zimberelimab is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

HAYWARD, Calif., December 19, 2024--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and ...

Marcus Rashford has set Barcelona a deadline to finalise terms as he looks to secure a Manchester United exit, ...